Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Aztreonam helps preserve lung function with bacterial infections

Treatment with the inhaled antibiotic aztreonam can stabilize lung function in people with cystic fibrosis (CF) who have chronic infections of the bacterium Pseudomonas aeruginosa. That’s according to “Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness,”…

Kaftrio treatment associated with fewer sinus surgeries

People with cystic fibrosis (CF) who have chronic inflammation in the nose are less likely to need sinus surgery if they are taking the triple-combination CFTR modulator treatment Kaftrio (elexacaftor/tezacaftor/ivacaftor). That’s according to “Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery…

First CF patient dosed with molecular prosthetic CM001

The first person with cystic fibrosis (CF) has been dosed with CM001, an experimental inhaled therapy being developed by Cystetic Medicines to treat all people with CF, including those who aren’t eligible for modulators. “Dosing the first person with CF represents a critical milestone in our mission to…

Chloride-transporting synthetic molecules show promise

Researchers have developed new synthetic molecules that can transport chloride salts across cell membranes, which showed promise for restoring normal mucus production in a cell model of cystic fibrosis (CF), a new study shows. “One day, [these molecules] could be leveraged into a drug that treats cystic fibrosis,” Bing…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.